Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160 For Treatment Of Autoimmune Diseases
Portfolio Pulse from Benzinga Newsdesk
Monte Rosa Therapeutics is advancing its second development candidate, MRT-6160, for the treatment of autoimmune diseases. The company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024.
May 23, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monte Rosa Therapeutics advances MRT-6160 for autoimmune diseases treatment, with plans to file an IND application in H1 2024.
Monte Rosa Therapeutics' advancement of MRT-6160 for autoimmune diseases treatment is a positive development for the company. The planned IND application in H1 2024 indicates progress in their pipeline, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100